Change of Largest Shareholder: ChaBioTech→Solux, Debt-Financed Acquisition

Largest shareholder changed from ChaBioTech (38.30%) to Solux (14.70%) on 2026.04.30.
Solux is an electric lighting company, unrelated to Cha Vaccine Research Institute.
Acquisition funding: W9.04B equity, W6.3B debt (from Unicorn Asset Loan Broker), collateralized by 3,948,813 shares of Cha Vaccine Research Institute.
Loan period: 2026.04.30~2026.07.29 (3 months), short-term borrowing.
Solux financials: 2025 sales W38.27B, net loss W7.72B, liabilities W50.69B, equity W90.89B.
ChaBioTech's remaining stake reduced to 4.99%.
New board appointed immediately at EGM: 5 inside directors, 2 outside directors, 1 auditor.